And Prozacs patent has expired about 5 years ago. I wonder the differential between drugs still under protection Like Zocor.
Prozac (fluoxetine) has patent protection as Sarafem (for premenstrual dysphoric disorder) and a new formulation Prozac Weekly.
To correct some misperceptions, Pfizer over the past few years has acquired:
Warner-Lambert
Parke-Davis
Pharmacia
Goedecke
Every acquisition actually REDUCES the total amount of resources committed to R&D. Without partnering with Big Pharma it is possible that some promising drug candidates from biotechs would not come to fruition. By the same token, mergers and acquisitions have DEFINITELY ended R&D into promising compounds. In essence, companies rarely finance competition with themselves.
Despite industry claims the vast majority of new chemical entities were not publicly funded, the substances, technology, and expertise invariably evolved from government investment. Legislation (like the Dole-Bayh Act) was designed to facility the development and transfer of technology to industry. I have three current projects for the off-label use of FDA-approved drugs and (six projects in development). My salary is funded by the NIH, although I do beg drug companies for free drug . . . b/c otherwise the studies would be impossible to finance. The research facilities I utilize for clinical trials and by bench research (molecular pharmacology) are constructed, staffed, and maintained on the government tab.
Here's an example of the farce. FDA-approved therapies for schizophrenia are typically approved based on clinical trials of several weeks up to a maximum of a couple of months. Clinical researchers (working at academic institutions) are the ones performing research to determine if these therapies are effective and safe long term. Thankfully, many drug companies donate drugs (and cash) to fund these studies but the major cashola comes from Uncle Sam.
It is true that a large portion of the expense in administration, marketing and advertisement comes from drug samples provided to clinicians that are subsequently given to patients. But drug companies deduct the RETAIL cost of these drugs which is reasonable to some extent but is questionable on other accounts. In my experience, clinicians do not discriminate in who gets samples. Drug companies are not providing samples out of the goodness of their hearts . . . they want doctors to give samples PLUS a prescription. Drug companies will argue they are providing vital medication to people who might not be able to afford it. That's true but clearly that's not their primary motivation. Well before a drug goes off patent, the supply of samples comes to a halt (I'm sure that's in a patient's best interests). Of course, a given companies followup product (say the move from Paxil to Paxil continuous release) quickly finds its way into the drug closet. So despite a patient's clear response to a therapy, clinicians (and patients) are coerced into changing to a different formulation. If you buy the drug companies argument about the expense of providing samples . . . maybe they should just stock the drug closet with the off patent version??
Admittedly, I've eaten more than a few drug lunches . . . and dinners. But truth be told some drug reps actually provide useful information . . . sometimes it's just a free meal. Annual conventions are particularly gratuitous. The last convention I attended looked like a circus in the industry pavillion. Of course, it's written off as just another expense . . . being recouped through high drug costs.
Under our current model, the profit motive does drive some advances. But it is not the primary reason our medications have improved over time. A case in point, a Canadian researcher was sued by a drug company b/c her research indicated their therapy was effective but extremely dangerous. Despite a clause in her contract that forbid her to release information without their consent, her morals compelled her to publish the findings. Of course, the rule of law prevailed . . . the drug company won their lawsuit. The drug was removed from the market.